> News


Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

(Cas) AEMPS: Información a los laboratorios titulares de Medicamentos de Uso Humano que contienen antagonistas del receptor de angiotensina-II (sartanes) con un grupo tetrazol: “candesartán, irbesartán, losartán, olmesartán y valsartán” (Nº EMA: EMEA/H/A-31/1471) – Actualización del procedimiento específico de implementación

Sorry, this entry is only available in European Spanish. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language. La [...]

Find out why Viglya is your strategic partner in drug development.Read more